RayKnowChina Research Map
Shortlist

Not yet recruitingPancreatic cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  2. Study siteRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07900789, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed pancreatic cancer originating from the pancreatic ductal epithelium.

    Inclusion criterion 5

  3. Received systemic immunosuppressive therapy within 14 days prior to randomization.

    Exclusion criterion 5

    Gastrointestinal obstruction within 6 months prior to initiation of study treatment, or current signs and symptoms of gastrointestinal obstruction.

    Exclusion criterion 8

    Major surgery (other than diagnostic procedure or biopsy) within 28 days prior to randomization; invasive minor surgery within 7 days prior to the first dose; or presence of a non-healing wound.

    Exclusion criterion 21

  4. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.

    Inclusion criterion 3

  5. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    Inclusion criterion 7

  6. Diagnosis of any other malignancy within 5 years prior to randomization.

    Exclusion criterion 12

    Active pulmonary tuberculosis infection within 1 year prior to enrollment.

    Exclusion criterion 16

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07900789, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Able to provide informed consent, with a signed and dated IRB/EC-approved informed consent form (ICF), and willing and able to comply with the scheduled visits, treatment plan, examinations, and other protocol-required procedures.
  • Aged between 18 and 75 years (inclusive) at the time of ICF signing; of either gender.
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
  • Expected survival of at least 6 months.
  • Histologically or cytologically confirmed pancreatic cancer originating from the pancreatic ductal epithelium.
  • High-risk resectable pancreatic cancer (HR-RPC) or borderline resectable pancreatic cancer (BRPC).
  • At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
  • Adequate major organ function meeting the protocol-specified criteria.-

Exclusion Criteria:

  • Prior systemic therapy for pancreatic cancer, including neoadjuvant chemotherapy or radiotherapy.
  • Distant metastatic lesions confirmed by imaging.
  • Has not recovered from the toxicity and/or complications of prior interventions to NCI-CTCAE Grade ≤ 1 or the level specified in the inclusion/exclusion criteria.
  • Currently has active autoimmune disease or a history of autoimmune disease with potential recurrence.
  • Received systemic immunosuppressive therapy within 14 days prior to randomization.
  • Known or suspected interstitial lung disease; or presence within 6 months prior to randomization of moderate-to-severe pulmonary diseases that may interfere with the detection or management of drug-related pulmonary toxicity or significantly impair respiratory function.
  • Symptomatic moderate or severe ascites; uncontrolled or moderate-to-large pleural effusion or pericardial effusion.
  • Gastrointestinal obstruction within 6 months prior to initiation of study treatment, or current signs and symptoms of gastrointestinal obstruction.
  • Clinically significant bleeding episodes or a clear bleeding tendency within 6 months prior to randomization.
  • Uncontrolled or severe cardiovascular/cerebrovascular disease, or arterial/venous thromboembolic events within 6 months prior to randomization; or arrhythmia, deep vein thrombosis, etc. requiring clinical intervention.
  • Carotid ultrasound demonstrating ≥ 50% stenosis, or carotid plaques with ≥ 2 high-risk features.
  • Diagnosis of any other malignancy within 5 years prior to randomization.
  • Serious infection within 28 days prior to the first dose; or active infection requiring therapeutic intravenous antibiotics within 2 weeks prior to initiation of study treatment.
  • Clinically significant acute or chronic pancreatitis.
  • Active hepatitis B or active hepatitis C.
  • Active pulmonary tuberculosis infection within 1 year prior to enrollment.
  • History of immunodeficiency or organ transplantation.
  • Active autoimmune disease requiring systemic treatment within 2 years prior to randomization.
  • Administration of a live attenuated vaccine within 28 days prior to randomization, or anticipated need for live attenuated vaccination during study treatment.
  • Participation in any other clinical drug trial within 4 weeks or 5 half-lives (whichever is longer) of the last study drug administration prior to randomization.
  • Major surgery (other than diagnostic procedure or biopsy) within 28 days prior to randomization; invasive minor surgery within 7 days prior to the first dose; or presence of a non-healing wound.
  • Known hypersensitivity to any component of HRS-4642; or known severe hypersensitivity to any of the combination antitumor agents (including SHR-1316, gemcitabine, and nab-paclitaxel).
  • Uncontrolled psychiatric illness, or known alcoholism, drug abuse, substance dependence, criminal detention, or other conditions that may interfere with completion of study procedures.

Quoted from ClinicalTrials.gov, NCT07900789, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07900789, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07900789